Viral safety of B-domain deleted recombinant factor VIII. 2001

T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
Genetics Institute, Cambridge, MA 01810, USA.

The possible transmission of blood-borne pathogens has been the impetus behind the development of recombinant products formulated in the absence of human-derived components. The viral safety of Chinese hamster ovary (CHO)-cell-based pharmaceuticals is well established. Over 100 million infusions have been administered without a single known incident of CHO-related viral transmission. The manufacturing process for B-domain deleted recombinant factor VIII (BDDrFVIII) builds on this safety record by using a state-of-the-art multitiered approach to viral safety. This approach includes: (1) extensive testing of the CHO cells used to produce BDDrFVIII; (2) routine viral monitoring of the cell culture production process; (3) a purification process in which a specific viral inactivation procedure has been included; (4) a final formulation that does not incorporate human albumin as the stabilizer; and (5) a thorough validation of the viral inactivation and removal capacity of the purification process. This multifaceted viral safety program offers the hemophilia community a factor VIII product with an exceptional degree of viral safety.

UI MeSH Term Description Entries
D008420 Manufactured Materials Substances and materials manufactured for use in various technologies and industries and for domestic use. Manufactured Material,Material, Manufactured,Materials, Manufactured
D003257 Consumer Product Safety The sum total of measures taken and regulatory policies enacted to ensure the safe use of consumer products. Safety, Consumer Product,Product Approval,Product Approvals,Product Safety, Consumer
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013242 Sterilization The destroying of all forms of life, especially microorganisms, by heat, chemical, or other means.
D016466 CHO Cells CELL LINE derived from the ovary of the Chinese hamster, Cricetulus griseus (CRICETULUS). The species is a favorite for cytogenetic studies because of its small chromosome number. The cell line has provided model systems for the study of genetic alterations in cultured mammalian cells. CHO Cell,Cell, CHO,Cells, CHO

Related Publications

T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
July 1997, Thrombosis and haemostasis,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
April 2001, Seminars in hematology,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
April 2001, Seminars in hematology,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
April 2001, Seminars in hematology,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
June 2002, Seminars in thrombosis and hemostasis,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
April 2001, Seminars in hematology,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
February 1997, Thrombosis and haemostasis,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
January 2002, Developments in biologicals,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
January 2000, Bioconjugate chemistry,
T S Charlebois, and B D O'connell, and S R Adamson, and H Brink-Nilsson, and M Jernberg, and B Eriksson, and B D Kelley
April 2001, Seminars in hematology,
Copied contents to your clipboard!